G-BA requested RWE collection for the second time – Fedratinib in myelofibrosis
Since 2020, the G-BA can request real-world evidence data collection in Germany. However, so far this was only implemented for one product,
Category: Early benefit assessments
Another cancer drug by Janssen unlikely to be available in Germany
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
Lung cancer drug taken off German market because of no additional benefit rating
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
G-BA defines 4 strict requirements on cefiderocol use to protect its “reserve antibiotics” status
Currently, reserve antibiotics are excluded from a benefit assessment by the G-BA. The G-BA decides whether to accept a new antibiotic onto the
IQWiG finds problems with the use of RWE in manufacturers’ dossiers
In this post, I’m following up on the key points on the real-world evidence (RWE) data collection in Germany with an IQWiG